

New Technology

Marc Bloomenstein OD, FAAO
Schwartz Laser Eye Center
Scottsdale, Arizona

DR. BLOOMENSTEIN'S Disclosure

- Presenter is on speakers panel of Alcon, Allergan, AMO, Bausch + Lomb, RFS, Reichert, Tear Lab
- President of MRB Eye Consultants
- Past-President of the Optometric Council on Refractive Technology (OCRT)
- Board Member of Ocular Surface Society of Optometry
- Presenter has NO financial interest in any products mentioned

Laser Assisted Cataract Surgery

- Traditional Cataract Surgery
 - Capsulotomy size directly related to Effective Lens Position
 - Corneal incisions are manually executed and imprecise
 - High level of phaco power can be associated with post-op complications



Cataract Complications

- PCO 10-30%
- CME transient 2-10%
- Vitreous loss 1-5%
- Corneal endothelial cell loss 4-10%
- Retinal detachment 0.6-1.7%
- CME persistent 1-2%
- IOL Malposition 0.3%
- Need for Corneal Transplant 0.3%
- Endophthalmitis 0.1%

Femtosecond Laser Technology

- LenSx:
- LensAR:
- Optimedica:
- Technolas:
- Nidek:

Femtosecond Cataract Surgery Capabilities

- Keratome Incision
- Paracentesis *
- Limbal Relaxing Incisions
- Anterior Capsulotomy
- Anterior Capsule Polishing *
- Nuclear Sectioning
- Posterior Capsulotomy *
- Vitreolysis *
- *Future application

Femtosecond Cataract Surgery: FDA Approved

- LenSx: Capsulotomy, Incision, Fragmentation
- LensAR: Fragmentation, Capsulotomy
- Victus: B & L Technolas: Capsulotomy, Incisions, Fragmentation and Lasik Flap
- Optimedica pending
- Nidek pending


Where and When to Use

- Pros and Cons of Femosecond Technology
 - Premium IOL
 - Toric
 - Multifocal
 - Monofocal IOL
 - Costs associated with technology




Intraoperative Wavefront aberrometry

- Standard and premium IOL calculations
 - Monofocal
 - .25diopter steps
 - Multifocal
 - Accommodating
 - Toric






ORA

Optwave Refractive Analysis
Wavetec Vision



“True” Aphakic Refractive Cylinder vs Corneal

- After Phaco Incision has been Made
- Measurement Combines **Anterior and Posterior** Contributions into a Single Value
- Measures line of sight not Apex
- **REFRACTIVE** Cylinder not Keratometric Cylinder
- **Makes No Assumptions About Index Changes like the Keratometric Index Does - We Just Measure It!**











LRI Application

- Most effective in Pseudophakic
- Least effective in phakic
- Titrate LRI to target

ORA Post LASIK Challenge

	Patient 1	Patient 2	Patient 3	Patient 4
ORA System's IOL Power Calculation	25.0 D	22.5 D	21.5 D	18.5 D
Patient's Post-Op Refraction	+0.25 D	-0.12 D	-0.25 D	-0.25 D
Surgeon 1 IOL Recommendation	24.5 D	20.5 D	20.0 D	18.0 D
Refraction Error	+0.45 D	+1.30 D	+0.75 D	+0.10 D
Surgeon 2 IOL Recommendation	24.5 D	21.0 D	22.5 D	19.0 D
Refraction Error	+0.45 D	+1.00 D	-0.90 D	-0.55 D
Surgeon 3 IOL Recommendation	24.5 D	22.0 D	21.0 D	19.5 D
Refraction Error	+0.45 D	+0.20 D	+0.10 D	-0.85 D







- ### ORA
- Increases Accuracy of Post-Surgical Outcomes – Improved Premium IOL Outcomes
 - Higher Level of Technology
 - Increased Cost to Patients
 - Increased Time in O.R.

The AcuFocus™ KAMRA™ Inlay

The KAMRA Inlay is limited by United States law to investigational use and not available for sale in the United States.


- ### Key Milestones & Developments
- Over 9000 inlays implanted worldwide
 - US IDE enrollment complete (507 patients)
 - Follow-up out to 24 months
 - Combination with LASIK has expanded the application of the KAMRA inlay from emmetropes to ametropes
 - New technology to ensure accurate centration



Proven Biocompatibility & Stability

- Verified by testing to FDA standards of ISO 11979 and 10993, including a 6-month rabbit corneal implant study
- Validated by clinical study results in over a 1000 subjects and extensive OCT studies
- Corneas are quiet after surgery and do not respond to the inlay material
- Photostability testing demonstrates exceptional UV resistance for the material to last a lifetime in vivo

PVDF is Biocompatible and Well Tolerated in the Intracorneal Space




Corneal Nutrition

- The corneal epithelium has the highest metabolic rate of any corneal cells
- The nutritional requirements of the cells in the cornea are supplied from the aqueous humor
- Important to allow for free flow of glucose and other metabolites to ensure corneal epithelial health


Corneal Nutrition

- Diffusion holes cover approximately 5% of the inlay area
- The hole pattern of the inlay allows proper diffusion of metabolites to support the health of all areas of the corneal epithelium



Light Transmission

- Allowing too much light transmission through a corneal inlay can degrade visual acuity and may cause night vision disturbances
- The KAMRA™ inlay allows:
 - Light transmission of only 5% in order to reduce symptoms of glare and halos
 - The perforations are arranged in a pseudo-random pattern to minimize diffraction which can contribute to night vision complaints




Foundations in Photography

- A photographic lens aperture is used to adjust the amount of light reaching the film or image sensor.
- Depth of field is a function of both the aperture and focal length of the camera lens
- Smaller apertures (larger F-Stop numbers) produce a longer depth of field




Correlating "F-Stop" to Pupil Size


- The pupil is the aperture of the human eye
- The iris is the diaphragm that serves as the aperture stop
- The entrance pupil can range from 2 mm to 8 mm depending on lighting conditions and iris response





Near Vision



Depth of Focus *without* Correction





Implantation Strategy

- The KAMRA™ Inlay is implanted **MONOCULARLY** in the **NON-DOMINANT** eye
- The fellow eye (dominant eye) may be emmetropic or ametropic
 - For ametropic eyes a LASIK procedure can be performed on the same day as inlay implantation

Pocket Procedure Overview


- A corneal pocket is small channel into the stroma
 - Approximately only 4.5 mm wide by 9.0 mm in length
- Technology requirements:
 - Femtosecond laser
 - High quality microscope
- Procedure time approximately 5-10 minutes

Objective Patient Selection Criteria

Pocket Procedure

Pre-Op Measure	Recommendation
Age	45 - 65
Spherical Equivalent	Plano to -1.00 D
Cylinder	$\leq 0.75 D$
K's	N/A
Axis	Correlates with location of surgical axis
Corneal thickness	> 500 microns
Residual bed	> 250 microns

- Stable refraction for minimum of 1 year
- No dry eye
- No ocular pathology



Possible Paradigm Shift

- Objective Lab Measurements of Ocular Surface Disease

CLIA Wavier for In-Office Lab Testing

- TearLab
- Adneo-Plus
- Additional Testing in Future
- Optometric Scope of Practice Laws

What is Dry Eye Disease?

Definition:

Dry eye is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface.

DEWS Report, Ocular Surface April 2007 Vol 6 No 2

Tear Hyperosmolarity- the Central Mechanism Causing Ocular Surface Inflammation, Cell Damage and Symptoms in Dry Eye Disease
 DEWS Report, 2007

Tear hyperosmolarity stimulates a cascade of inflammatory events
Inflammatory tear cytokines and MMPs
Apoptotic cell death
Reduced and altered tear mucins
Reduced lubrication
Up-regulation of HLA-DR expression on surface cells
Disruption of epithelial junctions
Intra-cytoplasmic changes in surface cells
Tear osmolality tracks severity of disease linearly and tracks response to therapy and is tightly linked to tear film instability

Hyperosmolarity in Dry Eye Diagnosis

Dry Eye Diagnosis

Saritosh Khanna,¹ Alan Tomlinson,¹ Angus McFadyen,² Charles Diaper,³ and Kannu Ramasub⁴

Purpose. To determine the most effective objective tests applied singly or in combination in the diagnosis of dry eye disease.

Methods. Two groups of subjects—41 with dry eye and 32 with no ocular surface disease—had objective tear film quality by evaporation, tear osmolarity rate (TR), volume and osmolarity, and mucinogen gland dropout score assessed.

Conclusions. Tear osmolarity is the best single test for the diagnosis of dry eye, whereas a history of non-employing a weighted combination of TR, evaporation, and osmolarity measurements derived from ocular surface disease severity is the most effective. *Ocular (Philadelphia) 19: 54* 2008;9: 1407-1414 DOI:10.1097/OCS.0b013e3181704055

Hyperosmolarity & Ocular Surface Damage

Hyperosmolarity-Induced Apoptosis in Human Corneal Epithelial Cells is Mediated by Cytochrome c and MAPK Pathways

Lihai Luo, MD,*†; De-Quan Li, MD, PhD,* and Stephen C. Pflugfelder, MD*

FIGURE 1. Apoptosis in corneal epithelial cells in normal epithelial cultures exposed to high-osmolarity saline solution media (175, 185, or 195 mOsm NaCl) for 24 hours, compared with cells cultured in normal medium. The percentage of positive cells in each group (n = 5) is shown in the graph. *P < 0.05, **P < 0.01, and ***P < 0.001. <http://dx.doi.org/10.1097/OCS.0b013e3181704055>

Hyperosmolarity as a Pro-inflammatory Stress

Hyperosmolar Saline Is a Proinflammatory Stress on the Mouse Ocular Surface

Lihai Luo, MD, De-Quan Li, MD, PhD, Rosa M. Corrales, PhD, and Stephen C. Pflugfelder, MD

FIGURE 1. IL-1β concentrations in tear fluid samples of mice before (untreated) and after treatment with isotonic salt solution (300 mOsm) or hyperosmolar saline solution (400, 500, 600, 700, 800, 900, 1000 mOsm) for 24 hours. The bar graph shows the relative expression of IL-1β in tear fluid. The mean and standard deviation (SD) values of these markers are shown in the bar graph. *P < 0.05, **P < 0.01, and ***P < 0.001. <http://dx.doi.org/10.1097/OCS.0b013e3181704055>

Osmolarity as a Gold Standard

The measurement of tear film osmolality arguably offers the best means of capturing, in a single parameter, the balance of input and output of the lacrimal system. It is clear from the comparison of the diagnostic efficiency of various tests for DED, used singly or in combination, that osmolality provides a powerful tool in the diagnosis of DED and has the potential to be accepted as a gold standard for the disease.

Alan Tomlinson, University, UK

Schirmer Strip Severity Analysis

$y = -38.375x + 24.905$
 $R^2 = 0.1698$

Tear Film Breakup Time (TBUT) Severity Analysis


$y = -28.755x + 14.965$
 $R^2 = 0.2987$

Corneal Staining Severity Analysis

$y = 18.442x - 3.0871$
 $R^2 = 0.4339$

Symptoms (OSDI) Severity Analysis

$y = 126.91x + 14.381$
 $R^2 = 0.4082$




Osmolarity in the Diagnosis of Dry Eye Disease

Clinical Test	PPV
Osmolarity	87%
Schirmers	31%
TBUT	25%
Staining	31%
Meniscus Height	33%




- Osmolarity is the "gold standard" test for Dry Eye
 - 45 years peer reviewed research
 - Osmolarity has been added to definition of Dry Eye
 - Global marker of Dry Eye, indicating a concentrated tear film


Source: OSW Report, Ocular Surface April 2007 Vol 5, 2. & Tenthara, A. et al., 2002, p. 2022



Utility of TearLab™ in Clinical Trials & Disease Management

- Osmolarity is a compelling choice for primary efficacy endpoint
 - Quantitative
 - Operator independent
 - Noninvasive (done at beginning of test sequence)
- Inclusion Criteria are Critical
 - One eye > 328 mOsm/L, Opposite eye > 316 mOsm/L
 - Different signs don't correlate in the general population
- Test TearLab™ Osmolarity before any other test
- Perform daily quality control
- Discontinue use of artificial tears at least 2 hours before testing





Place for Conventional Testing????

-
-
-
-

Improving the Diagnosis, Management, and Treatment of Infectious Conjunctivitis

Case
"Weeping, creeping and glass"


The Patient

A 44 y.o. "super cool" male
Presented to office with complaints of
"My eye hurts and it is uncomfortable"
"My eye is a little red and seems inflamed"

A physician
Self-treating
Self-diagnosing
All about himself



Super Cool Patient

Patient has no known medical problems
Mild head ache/jaw pain
No medications
No allergies
"This is the first time this has happened"
"Nobody else has this problem"
However...





The "Eye"

- Chemosis
- Glassy appearance
- Teary eye
- Mild swollen lids
- No C/F
- No papillary rxn
- Mild follicular

What's your diagnosis?

Iritis?
 Episcleritis?
 Bacterial Conjunctivitis?
 Allergic Conjunctivitis?
 Viral Conjunctivitis?



Not getting better....



Adenoviral Conjunctivitis

- Represents the most common external ocular infection¹
- Most frequent virus isolated from the conjunctiva²
- Prevalence varies based on time of year and geographic location³
- Adenovirus is associated with significant morbidity and high healthcare costs
- 20-65% of all conjunctivitis cases are viral²
 - As many as 90% of these may be Adenovirus³

[1] Gorman JL. The Cornea. J Pediatr 1994; 125:227-32. [2] Wessinger FR, Miller G, Johnson L. Arch Ophthalmol 2001; 119:106-10. [3] Infectious Agents Surveillance Report 2004;2(2):18

Adenovirus Transmission

- Can live on inanimate surfaces for 4-5 weeks¹
- Attack rates from 10-50%¹
- Stable to adverse chemical and physical conditions
- Can shed for 14-16 days after initial symptoms (**contagious!**)²
- Common modes of transmission:
 - Hand-to-eye
 - Airborne respiratory droplets

[1] O'Brien AD, Wang BK, McQuinn M, et al. West Am J Clin 2008 Aug;20(8):1153-61. [2] Ooster MK, Keeling GJ, Pavesoni A, et al. Am J Ophthalmol 2002;134(1):10-15

Spread of Disease

- Antibiotics are ineffective against treating the viral form of the disease but are prescribed in up to 95% of conjunctivitis cases³
- This leads many patients to return to school, work, or daycare while still contagious

A proper diagnosis and patient education can help stop the spread of infection!

[3] Smith K, Osher F. Fam Pract 2002;24(3):443

Misdiagnosis

- Misdiagnosis occurs in ~50% of conjunctivitis cases¹
- Significant overlap of signs and symptoms¹⁻³

Viral Conjunctivitis

- Upper Respiratory Infection: Viral 100%, Bacterial 5.9%
- Lymphadenopathy: Viral 37%, Bacterial 0%
- Watery Discharge: Viral 20%, Bacterial 39%
- Palpebral Edema: Viral 47%, Bacterial 42%

Bacterial Conjunctivitis

- Bilateral Infection: Viral 23%, Bacterial 55-74%
- Purulent Discharge: Viral 23-50%, Bacterial 28-67%

[1] Fisman T, Long M, McQuinn M, Robinson M. Can Med Assoc J. 2009;181(18):1293-1296. [2] Fitch TP, Mays PA, Owen L. Ophthalmology. 1988;95:1211-1220. [3] England J, Wilson M, Hooper P. J. Fam Pract. 1993;38:133-136.

Morbidity

- Unlike bacterial conjunctivitis, which is usually self-limiting, Adenoviral conjunctivitis is associated with significant morbidity such as:
 - Decreased visual acuity or light sensitivity from persistent subepithelial infiltrates¹
 - Chronic dry eye
 - Visual loss from conjunctival foreshortening and symblepharon formation (conjunctival scarring)²

[1] Wolf AL, Choudhri J. Cornea. 2003;22:199-202. [2] Hovvorn CA, Perry HG, Goodfellow EJ, Wolf AL. Cornea. 1993;12:69-70.

AdenoPlus

- Detects all known serotypes of Adenovirus
- Rapid – 10 minute results
- Easy to use – can be performed by a nurse or technician
- In-office (point-of-care) test
- Low cost – no additional equipment required
- One time use – disposable
- Accurate – high sensitivity and specificity
- Limit of detection – 6 ng/ml

How to Use AdenoPlus: Four-step Process

- Use a "dab and drag" motion in 6-8 locations on the palpebral conjunctiva (lower eyelid) to collect a tear sample.
- Snap the sample collector into the test cassette and press firmly where indicated.
- Dip the test cassette into the provided buffer vial for 30 seconds. Replace the cap.
- Read the results: 2 lines (1 red, 1 blue) = positive, 1 line (blue) = negative

AdenoPlus Clinical Trials™


A prospective, multicenter, masked, sequential, clinical trial was performed at a combination of private ophthalmology practices and academic centers.

The study enrolled 128 patients presenting with a clinical diagnosis of acute viral conjunctivitis.

Thirty-one patients were confirmed positive for Adenovirus by viral cell culture.

AdenoPlus	Cell Culture	
	+	-
	28	4
	3	93
Sensitivity	90% (28/31) 95% CI [74.2-98.0]	
Specificity	96% (93/97) 95% CI [89.8-98.9]	
Negative Predictive Value	97% (93/96) 95% CI [91.1-99.3]	
Positive Predictive Value	88% (28/32) 95% CI [71.0-96.5]	

[1] Hovvorn CA, et al. American Journal of Ophthalmology. 2004. 137(5): 659-668. [2] Fitch TP, et al. Cornea. 2005. 24(10): 1307-1311. [3] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2101-2106. [4] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2107-2111. [5] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2112-2116. [6] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2117-2121. [7] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2122-2126. [8] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2127-2131. [9] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2132-2136. [10] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2137-2141. [11] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2142-2146. [12] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2147-2151. [13] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2152-2156. [14] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2157-2161. [15] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2162-2166. [16] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2167-2171. [17] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2172-2176. [18] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2177-2181. [19] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2182-2186. [20] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2187-2191. [21] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2192-2196. [22] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2197-2201. [23] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2202-2206. [24] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2207-2211. [25] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2212-2216. [26] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2217-2221. [27] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2222-2226. [28] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2227-2231. [29] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2232-2236. [30] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2237-2241. [31] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2242-2246. [32] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2247-2251. [33] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2252-2256. [34] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2257-2261. [35] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2262-2266. [36] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2267-2271. [37] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2272-2276. [38] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2277-2281. [39] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2282-2286. [40] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2287-2291. [41] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2292-2296. [42] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2297-2301. [43] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2302-2306. [44] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2307-2311. [45] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2312-2316. [46] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2317-2321. [47] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2322-2326. [48] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2327-2331. [49] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2332-2336. [50] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2337-2341. [51] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2342-2346. [52] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2347-2351. [53] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2352-2356. [54] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2357-2361. [55] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2362-2366. [56] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2367-2371. [57] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2372-2376. [58] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2377-2381. [59] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2382-2386. [60] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2387-2391. [61] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2392-2396. [62] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2397-2401. [63] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2402-2406. [64] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2407-2411. [65] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2412-2416. [66] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2417-2421. [67] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2422-2426. [68] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2427-2431. [69] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2432-2436. [70] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2437-2441. [71] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2442-2446. [72] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2447-2451. [73] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2452-2456. [74] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2457-2461. [75] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2462-2466. [76] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2467-2471. [77] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2472-2476. [78] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2477-2481. [79] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2482-2486. [80] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2487-2491. [81] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2492-2496. [82] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2497-2501. [83] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2502-2506. [84] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2507-2511. [85] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2512-2516. [86] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2517-2521. [87] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2522-2526. [88] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2527-2531. [89] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2532-2536. [90] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2537-2541. [91] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2542-2546. [92] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2547-2551. [93] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2552-2556. [94] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2557-2561. [95] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2562-2566. [96] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2567-2571. [97] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2572-2576. [98] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2577-2581. [99] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2582-2586. [100] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2587-2591. [101] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2592-2596. [102] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2597-2601. [103] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2602-2606. [104] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2607-2611. [105] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2612-2616. [106] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2617-2621. [107] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2622-2626. [108] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2627-2631. [109] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2632-2636. [110] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2637-2641. [111] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2642-2646. [112] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2647-2651. [113] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2652-2656. [114] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2657-2661. [115] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2662-2666. [116] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2667-2671. [117] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2672-2676. [118] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2677-2681. [119] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2682-2686. [120] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2687-2691. [121] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2692-2696. [122] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2697-2701. [123] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2702-2706. [124] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2707-2711. [125] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2712-2716. [126] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2717-2721. [127] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2722-2726. [128] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2727-2731. [129] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2732-2736. [130] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2737-2741. [131] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2742-2746. [132] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2747-2751. [133] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2752-2756. [134] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2757-2761. [135] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2762-2766. [136] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2767-2771. [137] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2772-2776. [138] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2777-2781. [139] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2782-2786. [140] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2787-2791. [141] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2792-2796. [142] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2797-2801. [143] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2802-2806. [144] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2807-2811. [145] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2812-2816. [146] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2817-2821. [147] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2822-2826. [148] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2827-2831. [149] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2832-2836. [150] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2837-2841. [151] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2842-2846. [152] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2847-2851. [153] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2852-2856. [154] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2857-2861. [155] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2862-2866. [156] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2867-2871. [157] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2872-2876. [158] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2877-2881. [159] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2882-2886. [160] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2887-2891. [161] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2892-2896. [162] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2897-2901. [163] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2902-2906. [164] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2907-2911. [165] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2912-2916. [166] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2917-2921. [167] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2922-2926. [168] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2927-2931. [169] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2932-2936. [170] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2937-2941. [171] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2942-2946. [172] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2947-2951. [173] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2952-2956. [174] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2957-2961. [175] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2962-2966. [176] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2967-2971. [177] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2972-2976. [178] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2977-2981. [179] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2982-2986. [180] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2987-2991. [181] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2992-2996. [182] Wolf AL, et al. Ophthalmology. 2005. 112(12): 2997-3001. [183] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3002-3006. [184] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3007-3011. [185] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3012-3016. [186] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3017-3021. [187] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3022-3026. [188] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3027-3031. [189] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3032-3036. [190] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3037-3041. [191] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3042-3046. [192] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3047-3051. [193] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3052-3056. [194] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3057-3061. [195] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3062-3066. [196] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3067-3071. [197] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3072-3076. [198] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3077-3081. [199] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3082-3086. [200] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3087-3091. [201] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3092-3096. [202] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3097-3101. [203] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3102-3106. [204] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3107-3111. [205] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3112-3116. [206] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3117-3121. [207] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3122-3126. [208] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3127-3131. [209] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3132-3136. [210] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3137-3141. [211] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3142-3146. [212] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3147-3151. [213] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3152-3156. [214] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3157-3161. [215] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3162-3166. [216] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3167-3171. [217] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3172-3176. [218] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3177-3181. [219] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3182-3186. [220] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3187-3191. [221] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3192-3196. [222] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3197-3201. [223] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3202-3206. [224] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3207-3211. [225] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3212-3216. [226] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3217-3221. [227] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3222-3226. [228] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3227-3231. [229] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3232-3236. [230] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3237-3241. [231] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3242-3246. [232] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3247-3251. [233] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3252-3256. [234] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3257-3261. [235] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3262-3266. [236] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3267-3271. [237] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3272-3276. [238] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3277-3281. [239] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3282-3286. [240] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3287-3291. [241] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3292-3296. [242] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3297-3301. [243] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3302-3306. [244] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3307-3311. [245] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3312-3316. [246] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3317-3321. [247] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3322-3326. [248] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3327-3331. [249] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3332-3336. [250] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3337-3341. [251] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3342-3346. [252] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3347-3351. [253] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3352-3356. [254] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3357-3361. [255] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3362-3366. [256] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3367-3371. [257] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3372-3376. [258] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3377-3381. [259] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3382-3386. [260] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3387-3391. [261] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3392-3396. [262] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3397-3401. [263] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3402-3406. [264] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3407-3411. [265] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3412-3416. [266] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3417-3421. [267] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3422-3426. [268] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3427-3431. [269] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3432-3436. [270] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3437-3441. [271] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3442-3446. [272] Wolf AL, et al. Ophthalmology. 2005. 112(12): 3447-3451. [273] Wolf AL, et al. Ophthalmology. 2005. 112(12



Normal Levels of MMP-9

Literature supports that the normal levels of MMP-9 (ng/ml) in human controls range from 3-41 ng/ml

Study	Normal Controls	Average MMP-9 Levels (ng/ml)	Standard Deviation (ng/ml)	Upper Range (ng/ml)
Acera et al 2008	18	23.6	17.4	41.0
Chotkavonich et al 2009	16	8.4	4.7	13.0
Schlosser et al 2001	17	7.2	2.1	9.0
Leung et al 2009	19	10.5	6.2	11.0
Sato et al 2009	20	6.9	1.4	9.0
Honda et al 2010	28	22.7	14.0	37.0
Markouli et al 2010	38	11.6	5.2	N/A
Total/Avg/Range	147	12.9 ng/ml	-	41.0 ng/ml

MMP-9 and Dry Eye Severity¹

Patient's Dysfunctional Tear Syndrome Level	Average MMP-9 Level	Statistical Significance vs Normal
Normal (n=18)	8.39 ng/ml	NO
Severity Level 1 (n=15)	35.57 ng/ml	NO
Severity Level 2 (n=11)	66.17 ng/ml	YES
Severity Level 3 (n=9)	101.42 ng/ml	YES
Severity Level 4 (n=11)	381.24 ng/ml	YES

Positive Result = Chronic Dry Eye
≥ 40 ng/ml

1) Chotkavonich L, et al. Invest Ophthalmol Vis Sci. 2009; 50(12):3088-3090.

InflammaDry

- Detects elevated levels of MMP-9 in tear fluid
- 10 minute in-office results
- Easy to use – can be performed by technicians or nurses
- Disposable – no additional equipment required

Limit of Detection: the normal level of MMP-9 in human tears ranges from 3-41 ng/ml

- **Positive** test result = MMP-9 ≥ 40 ng/ml
- **Negative** test result = MMP-9 <40 ng/ml

InflammaDry is CE Marked and commercially available in Europe. At this time InflammaDry is pending 510(k) review by FDA and is not commercially available in the U.S.

How to Use InflammaDry: Four-step Process

1. Gently dab the Sample Collector in 6-8 locations on the palpebral conjunctiva (lower eyelid) to collect a tear sample. Do not use a dragging motion.
2. Snap the sample collector into the test cassette and press firmly where indicated.
3. Dip the test cassette into the provided buffer vial for 20 seconds. Replace the cap.
4. Read the results: 2 lines (1 red, 1 blue) = positive, 1 line (blue) = negative

InflammaDry Clinical Trial

N = 206	Clinical Criteria	
	+	-
InflammaDry	+	4
	-	59
Sensitivity		85% (121/143)
Specificity		94% (59/63)
Overall Agreement		87% (180/206)

Other Methods for Dry Eye Diagnosis¹

Dry Eye Testing Method	Sensitivity	Specificity
Schirmer Tear Test	42%	76%
Tear Break Up Time	92%	17%
Corneal Staining	63%	89%
Questionnaire	89%	72%
TearLab Osmolarity ^{2,3}	64-73%	71-92%

InflammaDry Sensitivity Specificity

1) Versura P, Fogarty M, Collins M, et al. Diagnostic performance of tear function tests in Sjogren's syndrome patients. Eye Contact Lens. 2002;28:229-31.
2) Versura P, Fogarty M, Collins M, et al. Diagnostic performance of tear function tests in Sjogren's syndrome patients. Eye Contact Lens. 2002;28:229-31.
3) Versura P, Fogarty M, Collins M, et al. Diagnostic performance of tear function tests in Sjogren's syndrome patients. Eye Contact Lens. 2002;28:229-31.

Treatment of Dry Eye

- Elevated MMP-9 may predict which patients will respond to anti-inflammatory therapy
- Patients who test positive can be treated with one of the following:^{1,3}
 - Cyclosporine, Steroid, or Doxycycline

1) Versura P, Fogarty M, Collins M, et al. Eye Contact Lens. 2004;30(1):126-31. 2) Gao J, Gao J, Gao J, et al. Current Eye Research. 2010; 35(10):1177-1182. 3) Versura P, Fogarty M, Collins M, et al. Invest Ophthalmol Vis Sci. 2002; 43(11):2401-2408.

Cyclosporine and MMP-9

MMP-9 expression was evaluated by immunohistochemistry. The mean percentage of MMP-9 expression of the conjunctival epithelial cells was significantly decreased.

MMP-9 expression was evaluated semi-quantitatively by measuring cytoplasmic staining for MMP-9.

N=24 eyes of patients with thyroid orbitopathy-related dry eye

1) Gao J, Gao J, Gao J, et al. Ocular surface and dry eye in Sjogren's disease. Curr Eye Res. 2011; 36:1-13.

Detecting Elevated Levels of MMP-9


Identifying elevated levels of MMP-9 facilitates better management of:



- Patients who present with signs or symptoms of dry eye
- Patients having ocular surgery such as LASIK or cataract surgery



Dry Eye/Ocular Surface Disease Patient Management



Ocular Surgery Complications

If elevated levels of MMP-9 are not tested and confirmed to identify and treat dry eye prior to ocular surgery, the following complications may occur:

- Less accurate pre-surgical measurements lead to worse visual acuity outcomes¹
- Mild dry eye becomes severe dry eye²
- Asymptomatic dry eye becomes symptomatic chronic dry eye²
- Poor epithelial healing³
- Epithelial ingrowth³
- LASIK flap slippage³

1) Toller A, Goldberg S, Healy C. Incidence of elevated central and dry eye preoperative health assessment of cataract patients. Presented World Vision Conference, April 2010, Boston, MA. 2) Anderson R. Medical Surg 2008. 3) Shekh-Hafiz M, Khorrami M, Sankarankrishnan M, et al. Arch Ophthalmol 2010. 439-446-450.

Clinician Benefits

Potential benefits of detecting elevated levels of MMP-9 and initiating treatment to optimize the ocular surface:

- Clinical advantage
 - Better outcomes
 - Reduced complications
 - Safer and better patient care
- Marketing advantage
 - Differentiates from competition
 - Optimal preoperative screening and perioperative management
- Economic advantage
 - Less complications
 - Less follow up/repeat visits for "unhappy" patients



ORA

Ocular Response Analyzer
Reichert, NY

Elasticity

Elasticity: The property of a substance that enables it to change its length, volume, or shape in direct response to a force, and to recover its original form upon the removal of the force.



Strain (deformation) is directly proportional to stress (applied force), independent of the length of time or the rate at which the force is applied.

Viscosity and Damping

Viscosity: Resistance of a fluid (liquid or gas) to a change in shape, or movement of neighboring portions relative to one another. The more viscous a fluid is, the more it resists flow.
Honey, for example, has a greater viscosity than water.
Resistance to an applied force depends primarily on the speed at which the force is applied.



Damping: restraining of vibratory motion, such as mechanical oscillations, by dissipation of energy. Viscous fluids or gasses are employed to accomplish this.

Visco-Elastic System

An Automotive "Strut" Assembly

- Coil Spring: Static Resistance (Elasticity)
- Shock Absorber: Viscous Resistance (Damping)



The Cornea is a Visco-Elastic System


Basic Parameters










- ORA
- IOP - Goldmann Correlated IOP
- IOP - Corneal Compensated IOP
- CH - Corneal Hysteresis
- CRF - Corneal Resistance Factor

ZCR Correlated IOP
IOP - Corneal Compensated IOP
•IOPG - Goldmann








Corneal Hysteresis: A New Ocular Parameter



The Cornea and IOP measurement



CH and Glaucoma



Thank you.....